Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dennis A Eichenauer

Showing results (71-80 of 122) with videos related to

Pageof 13
Sort By:
Cancer Research|January 11, 2007
ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy in vitroDennis A Eichenauer, Vijaya Lakshmi Simhadri, Elke Pogge von Strandmann, et al.
Hematological Oncology|March 21, 2022
Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study GroupDennis A Eichenauer, Ina Bühnen, Annette Plütschow, et al.
British Journal of Haematology|December 29, 2018
Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trialBoris Böll, Annette Plütschow, Carolin Bürkle, et al.
European Journal of Haematology|September 3, 2022
JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO)Sarah Gillessen, Annette Pluetschow, Vladan Vucinic, et al.
Blood|January 31, 2014
Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study GroupDennis A Eichenauer, Indra Thielen, Heinz Haverkamp, et al.
Mycoses|April 28, 2020
COVID-19 associated pulmonary aspergillosisPhilipp Koehler, Oliver A Cornely, Bernd W Böttiger, et al.
The European Respiratory Journal|February 11, 2022
<i>Aspergillus</i> tracheobronchitis in COVID-19 patients with acute respiratory distress syndrome: a cohort studyPhilipp Koehler, Saskia von Stillfried, Jorge Garcia Borrega, et al.
Blood|February 3, 2016
Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trialsBoris Böll, Helen Goergen, Karolin Behringer, et al.
Leukemia|June 10, 2026
Nodular lymphocyte-predominant Hodgkin lymphoma controversy and insights: a global NLPHL one working group summit reportJamie E Flerlage, Monica Palese, Suzi Birz, et al.
The Lancet. Haematology|March 26, 2021
Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14)Sarah Gillessen, Annette Plütschow, Michael Fuchs, et al.
Pageof 13

Showing results (71-80 of 122) with videos related to

Sort By:
Pageof 13
Cancer Research|January 11, 2007
ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy in vitroDennis A Eichenauer, Vijaya Lakshmi Simhadri, Elke Pogge von Strandmann, et al.
Hematological Oncology|March 21, 2022
Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study GroupDennis A Eichenauer, Ina Bühnen, Annette Plütschow, et al.
British Journal of Haematology|December 29, 2018
Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trialBoris Böll, Annette Plütschow, Carolin Bürkle, et al.
European Journal of Haematology|September 3, 2022
JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO)Sarah Gillessen, Annette Pluetschow, Vladan Vucinic, et al.
Blood|January 31, 2014
Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study GroupDennis A Eichenauer, Indra Thielen, Heinz Haverkamp, et al.
Mycoses|April 28, 2020
COVID-19 associated pulmonary aspergillosisPhilipp Koehler, Oliver A Cornely, Bernd W Böttiger, et al.
The European Respiratory Journal|February 11, 2022
<i>Aspergillus</i> tracheobronchitis in COVID-19 patients with acute respiratory distress syndrome: a cohort studyPhilipp Koehler, Saskia von Stillfried, Jorge Garcia Borrega, et al.
Blood|February 3, 2016
Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trialsBoris Böll, Helen Goergen, Karolin Behringer, et al.
Leukemia|June 10, 2026
Nodular lymphocyte-predominant Hodgkin lymphoma controversy and insights: a global NLPHL one working group summit reportJamie E Flerlage, Monica Palese, Suzi Birz, et al.
The Lancet. Haematology|March 26, 2021
Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14)Sarah Gillessen, Annette Plütschow, Michael Fuchs, et al.
Pageof 13